Phathom Pharmaceuticals (PHAT) Operating Expenses (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Operating Expenses data on file, last reported at $61.8 million in Q1 2026.

• On a quarterly basis, Operating Expenses fell 40.4% year-over-year to $61.8 million in Q1 2026; TTM through Mar 2026 was $270.6 million, a 24.19% decrease from a year earlier, with the FY2025 full-year figure at $312.5 million, down 3.77% from the prior year.
• Operating Expenses for Q1 2026 stood at $61.8 million, up from $55.9 million in the prior quarter.
• Over the last five years, Operating Expenses for PHAT reached as high as $103.7 million in Q1 2025 and fell as low as $30.1 million in Q1 2023.
• Historically, Operating Expenses has averaged $61.1 million across 5 years, with a median of $58.6 million in 2025.
• Across the five-year window, Operating Expenses jumped 162.6% in 2024 and plunged 40.4% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $46.6 million in 2022, then jumped by 50.92% to $70.4 million in 2023, then gained by 21.13% to $85.3 million in 2024, then tumbled by 34.48% to $55.9 million in 2025, then gained by 10.59% to $61.8 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $61.8 million in Q1 2026, $55.9 million in Q4 2025, and $58.6 million in Q3 2025.